At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03696 INSILICO
Market Closed 03-06 16:08:19
55.500
-0.600
-1.07%
High59.350Low54.650Vol3.66M
Open56.150D1 Closing56.100Amplitude8.38%
Mkt Cap31.73BTradable Cap31.73BTotal Shares571.62M
T/O207.37MT/O Rate0.64%Tradable Shares571.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
INSILICO (03696) Issues Profit Warning, Citing Fair Value Changes and Revenue Decline
Bulletin Express  ·  03-06 22:43
INSILICO (03696) Issues Profit Warning, Citing Fair Value Changes and Revenue Decline
BRIEF-Insilico Medicine Cayman TopCo Expects FY Loss Attributable Of USD352.1 MLN-USD355.8 MLN
Reuters  ·  03-06 22:34
BRIEF-Insilico Medicine Cayman TopCo Expects FY Loss Attributable Of USD352.1 MLN-USD355.8 MLN
Insilico Medicine Cayman Topco - Expects FY Loss Attributable of USD352.1 Mln-USD355.8 Mln
THOMSON REUTERS  ·  03-06 22:31
Insilico Medicine Cayman Topco - Expects FY Loss Attributable of USD352.1 Mln-USD355.8 Mln
Insilico Medicine expects 2025 revenue of $55.8-56.3 million and loss attributable to owners of $352.1-355.8 million
Reuters  ·  03-06 22:30
Insilico Medicine expects 2025 revenue of $55.8-56.3 million and loss attributable to owners of $352.1-355.8 million
Insilico and Taigen Achieve Milestone in Collaboration: Out-Licensed Ckd Anemia Candidate ISM4808 Completes First Human Enrollment and Dosing in Phase I Clinical Trial
THOMSON REUTERS  ·  03-06 18:53
Insilico and Taigen Achieve Milestone in Collaboration: Out-Licensed Ckd Anemia Candidate ISM4808 Completes First Human Enrollment and Dosing in Phase I Clinical Trial
Prospective Adjustments to Hong Kong Stock Connect in March: 44 Stocks Poised for Inclusion, Featuring Insilico (03696) and JD Industrials (07618)
Stock News  ·  03-06 14:32
Prospective Adjustments to Hong Kong Stock Connect in March: 44 Stocks Poised for Inclusion, Featuring Insilico (03696) and JD Industrials (07618)
INSILICO Achieves Milestone in Collaboration with TaiGen as CKD Anemia Drug ISM4808 Doses First Patient in Phase I Trial
Stock News  ·  03-06 08:06
INSILICO Achieves Milestone in Collaboration with TaiGen as CKD Anemia Drug ISM4808 Doses First Patient in Phase I Trial
INSILICO (03696) and TaiGen (4157.TWO) Advance CKD Anemia Candidate ISM4808 into Phase I Trial
Bulletin Express  ·  03-06 08:02
INSILICO (03696) and TaiGen (4157.TWO) Advance CKD Anemia Candidate ISM4808 into Phase I Trial
Insilico and TaiGen Dose First Patient in Phase I Trial of ISM4808 for CKD Anemia
Reuters  ·  03-06 08:00
Insilico and TaiGen Dose First Patient in Phase I Trial of ISM4808 for CKD Anemia
INSILICO (03696) Announces February 2026 Securities Movements
Bulletin Express  ·  03-05 17:49
INSILICO (03696) Announces February 2026 Securities Movements
INSILICO Shares Surge Nearly 6% Following Strategic Collaboration Intent with UAE Health Authority
Stock News  ·  03-05 10:38
INSILICO Shares Surge Nearly 6% Following Strategic Collaboration Intent with UAE Health Authority
Assessing InSilico Medicine Cayman TopCo (SEHK:3696) Valuation After Strong Year To Date Share Price Gains
Simply Wall St.  ·  02-25
Assessing InSilico Medicine Cayman TopCo (SEHK:3696) Valuation After Strong Year To Date Share Price Gains
InSilico Medicine to Join Hang Seng Index
MT Newswires Live  ·  02-20
InSilico Medicine to Join Hang Seng Index
Hong Kong Stock Announcement Highlights: Insilico, Seyond, and CF Pharmtech Added to Hang Seng Composite Index Constituents
Stock News  ·  02-20
Hong Kong Stock Announcement Highlights: Insilico, Seyond, and CF Pharmtech Added to Hang Seng Composite Index Constituents
InSilico Medicine (3696) Selected for Inclusion in Hang Seng Composite Index
Bulletin Express  ·  02-20
InSilico Medicine (3696) Selected for Inclusion in Hang Seng Composite Index
INSILICO to Join Hang Seng Composite Index Constituents
Stock News  ·  02-20
INSILICO to Join Hang Seng Composite Index Constituents
**Insilico Medicine Cayman TopCo Joins Hang Seng Composite Index**Insilico Medicine Cayman TopCo said it has been selected for inclusion in the Hang Seng Composite Index, effective March 9, 2026. The company added that the move is expected to help its shares meet eligibility criteria for trading via the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect
Reuters  ·  02-20
**Insilico Medicine Cayman TopCo Joins Hang Seng Composite Index**Insilico Medicine Cayman TopCo said it has been selected for inclusion in the Hang Seng Composite Index, effective March 9, 2026. The company added that the move is expected to help its shares meet eligibility criteria for trading via the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect
Insilico Medicine CMS Alliance Tests Investor Faith In AI Drug Pipeline
Simply Wall St.  ·  02-19
Insilico Medicine CMS Alliance Tests Investor Faith In AI Drug Pipeline
Assessing InSilico Medicine Cayman TopCo (SEHK:3696) Valuation After A Strong Momentum-Driven Share Price Rally
Simply Wall St.  ·  02-16
Assessing InSilico Medicine Cayman TopCo (SEHK:3696) Valuation After A Strong Momentum-Driven Share Price Rally
BUZZ-InSilico hits fresh high on partnership deal with China Medical
Reuters  ·  02-10
BUZZ-InSilico hits fresh high on partnership deal with China Medical

Introduction

Company Name.
INSILICO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
InSilico Medicine Cayman TopCo is a company principally engaged in the research and development of artificial intelligence in pharmaceuticals. The Company is engaged in the research and development of drug discovery engines. In addition, the Company is engaged in the copabdrug discovery and development of disease target identification, generation of novel molecules data, and predicting clinical trial outcomes.
Issue price:
--